Figure 6
Figure 6. Survival analysis for Epo-administered, erythroleukemic mice. BALB/cJ neonates were inoculated with F-MuLV and grouped as experimental and control (n > 4 mice/group). On week 6 after viral infection, the mice in the experimental group were treated with 50 IU recombinant Epo, 3 times a week for a 3-week period. (A) A Kaplan-Meier survival curve was plotted for untreated and Epo-treated erythroleukemic mice. Mice were monitored on a daily basis and killed according to institutional guidelines. (B) On week 8 all mice were bled by tail veins, and hematocrits were measured using hematocrit tubes. (C) Spleens from all mice killed on day 100 (or at end point in the case of untreated controls) were harvested, and their weights were measured and plotted. **P < .05.

Survival analysis for Epo-administered, erythroleukemic mice. BALB/cJ neonates were inoculated with F-MuLV and grouped as experimental and control (n > 4 mice/group). On week 6 after viral infection, the mice in the experimental group were treated with 50 IU recombinant Epo, 3 times a week for a 3-week period. (A) A Kaplan-Meier survival curve was plotted for untreated and Epo-treated erythroleukemic mice. Mice were monitored on a daily basis and killed according to institutional guidelines. (B) On week 8 all mice were bled by tail veins, and hematocrits were measured using hematocrit tubes. (C) Spleens from all mice killed on day 100 (or at end point in the case of untreated controls) were harvested, and their weights were measured and plotted. **P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal